Compare AER & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | RPRX |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4B | 19.7B |
| IPO Year | 2006 | 2020 |
| Metric | AER | RPRX |
|---|---|---|
| Price | $136.58 | $45.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $150.29 | $47.75 |
| AVG Volume (30 Days) | 1.4M | ★ 2.9M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 1.22% | ★ 2.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | N/A | $38.30 |
| Revenue Next Year | $1.53 | $4.80 |
| P/E Ratio | ★ $7.27 | $25.45 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $85.57 | $29.66 |
| 52 Week High | $154.94 | $47.86 |
| Indicator | AER | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 53.21 |
| Support Level | $130.97 | $44.94 |
| Resistance Level | $138.34 | $46.14 |
| Average True Range (ATR) | 4.24 | 0.83 |
| MACD | -0.44 | -0.24 |
| Stochastic Oscillator | 29.90 | 35.28 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.